HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

NCT06389500 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Adebrelimab
DRUG: Lenvatinib
PROCEDURE: Hepatic Arterial Infusion Chemotherapy

Sponsor

Harbin Medical University